ReviewJournal of molecular medicine (Berlin, Germany)2009
Brain cancer stem cells.
Review in Journal of molecular medicine (Berlin, Germany), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Review
- Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation.International journal of molecular sciences · 2023Article
- Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.PloS one · 2021Article
- Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges.Frontiers in oncology · 2021Review
- Autophagy in cancers including brain tumors: role of MicroRNAs.Cell communication and signaling : CCS · 2020Review
- Review
- Knockdown of long non-coding RNA PCAT1 in glioma stem cells promotes radiation sensitivity.Medical molecular morphology · 2019Article
- The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma.Oncotarget · 2017Article
- Multidrug-resistant cancer cells and cancer stem cells hijack cellular systems to circumvent systemic therapies, can natural products reverse this?Cellular and molecular life sciences : CMLS · 2017Review
- Suppressing H19 Modulates Tumorigenicity and Stemness in U251 and U87MG Glioma Cells.Cellular and molecular neurobiology · 2016Article
- Stem cell-based therapies for tumors in the brain: are we there yet?Neuro-oncology · 2016Review
- Cancer Stem Cell Hierarchy in Glioblastoma Multiforme.Frontiers in surgery · 2016Review
- Article
- CD15 Expression Does Not Identify a Phenotypically or Genetically Distinct Glioblastoma Population.Stem cells translational medicine · 2015Article
- Dedifferentiation of patient-derived glioblastoma multiforme cell lines results in a cancer stem cell-like state with mitogen-independent growth.Journal of cellular and molecular medicine · 2015Article
- Autophagy Induction by Endothelial-Monocyte Activating Polypeptide II Contributes to the Inhibition of Malignant Biological Behaviors by the Combination of EMAP II with Rapamycin in Human Glioblastoma.Frontiers in molecular neuroscience · 2015Article
- Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.Cancer research · 2015Article
- Evaluation of cytotoxic properties of a cyclopamine glucuronide prodrug in rat glioblastoma cells and tumors.Journal of molecular neuroscience : MN · 2015Article
- Identification of U251 glioma stem cells and their heterogeneous stem-like phenotypes.Oncology letters · 2013Article
- ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma.Experimental hematology & oncology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers comprise heterogeneous cells, ranging from highly proliferative immature precursors to more differentiated cell lineages. In the last decade, several groups have demonstrated the existence of cancer stem cells in both nonsolid solid tumors, including some of the brain: glioblastoma multiforme (GBM), medulloblastoma, and ependymoma. These cells, like their normal counterpart in homologous tissues, are multipotent, undifferentiated, self-sustaining, yet transformed cells. In particular, glioblastoma-stem like cells (GBSCs) self-renew under clonal conditions and differentiate into neuron- and glia-like cells, with aberrant, mixed neuronal/astroglial phenotypes. Remarkably, upon subcutaneous and intracerebral transplantation in immunosuppressed mice, GBSCs are able to form secondary tumors that closely resemble the human pathology, a property retained also throughout serial transplantation. The search is up for the identification of the markers and the molecular mechanisms that underpin the tumorigenic potential of these cells. This is critical if we aim at defining new therapeutic approaches for the treatment of malignant brain tumors. Lately, it has been shown that some key regulatory system that plays pivotal roles in neural stem cell physiology can also regulate the tumorigenic ability of cancer stem cells in GBMs. This suggests that the study of cancer stem cells in brain tumors might help to identify new and more specific therapeutic molecular effectors, with the cancer stem cells themselves representing one of the main targets, in fact the Holy Grail, in cancer cell therapy. This review includes a summary review on brain cancer cells and their usefulness as emerging targets in cancer cell therapy.
Indexed as
Identifiers
19784875What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.